Literature DB >> 35534704

The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.

Jarbas Maciel de Oliveira1,2, Nuria Bengala Zurro3, Antonio Victor Campos Coelho3, Marcel Pinheiro Caraciolo3, Rodrigo Bertollo de Alexandre3, Murilo Castro Cervato3, Renata Moldenhauer Minillo3, George de Vasconcelos Carvalho Neto3, Ivana Grivicich4, João Bosco Oliveira5.   

Abstract

Hereditary cancer risk syndromes are caused by germline variants, commonly in tumor suppressor genes. Most studies on hereditary cancer have been conducted in white populations. We report the largest study in Brazilian individuals with multiple ethnicities. We genotyped 1682 individuals from all country regions with Next-generation sequencing (NGS) panels. Most were women with a personal/family history of cancer, mostly breast and ovarian. We identified 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%) distributed among 32 genes. Most were on BRCA1 and BRCA2 (129 patients, 26.2% and 14.3% of all P/LP, respectively), MUTYH (42 monoallelic patients, 13.1%), PALB2 (25, 7.8%), Lynch syndrome genes (17, 5.3%), and TP53 (17, 5.3%). Transheterozygosity prevalence in our sample was 0.89% (15/1682). BRCA1/BRCA2 double heterozygosity rate was 0.78% (1/129) for BRCA variants carriers and 0.06% (1/1682) overall. We evaluated the performance of the genetic testing criteria by NCCN and the Brazilian National Health Agency (ANS). The inclusion criteria currently used in Brazil fail to identify 17%-25% of carriers of P/LP variants in hereditary cancer genes. Our results add knowledge on the Brazilian spectrum of cancer risk germline variants, demonstrate that large multigene panels have high positivity rates, and indicate that Brazilian inclusion criteria for genetic testing should be improved.
© 2022. The Author(s), under exclusive licence to European Society of Human Genetics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35534704      PMCID: PMC9259741          DOI: 10.1038/s41431-022-01098-7

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   5.351


  30 in total

1.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

2.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Authors:  G Parmigiani; D Berry; O Aguilar
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

3.  Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.

Authors:  Jae Myoung Noh; Doo Ho Choi; Seok Jin Nam; Jeong Eon Lee; Jong Won Kim; Sung-Won Kim; Eunyoung Kang; Min Hyuk Lee; Sei Hyun Ahn; Ku Sang Kim; Sue K Park; Bruce G Haffty
Journal:  Breast Cancer Res Treat       Date:  2011-08-17       Impact factor: 4.872

4.  Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.

Authors:  Anna P Sokolenko; Natalia Bogdanova; Wojciech Kluzniak; Elena V Preobrazhenskaya; Ekatherina S Kuligina; Aglaya G Iyevleva; Svetlana N Aleksakhina; Natalia V Mitiushkina; Tatiana V Gorodnova; Alexandr A Bessonov; Alexandr V Togo; Jan Lubiński; Cezary Cybulski; Anna Jakubowska; Thilo Dörk; Evgeny N Imyanitov
Journal:  Breast Cancer Res Treat       Date:  2014-05-07       Impact factor: 4.872

5.  Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.

Authors:  Shan Yang; Jennifer E Axilbund; Erin O'Leary; Scott T Michalski; Robbie Evans; Stephen E Lincoln; Edward D Esplin; Robert L Nussbaum
Journal:  Ann Surg Oncol       Date:  2018-07-11       Impact factor: 5.344

6.  Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil.

Authors:  Crisle Vignol Dillenburg; Isabel Cristina Bandeira; Taiana Valente Tubino; Luciana Grazziotin Rossato; Eleonora Souza Dias; Ana Cristina Bittelbrunn; Sandra Leistner-Segal
Journal:  Genet Mol Biol       Date:  2012-08-17       Impact factor: 1.771

7.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.

Authors:  Lisa R Susswein; Megan L Marshall; Rachel Nusbaum; Kristen J Vogel Postula; Scott M Weissman; Lauren Yackowski; Erica M Vaccari; Jeffrey Bissonnette; Jessica K Booker; M Laura Cremona; Federica Gibellini; Patricia D Murphy; Daniel E Pineda-Alvarez; Guido D Pollevick; Zhixiong Xu; Gabi Richard; Sherri Bale; Rachel T Klein; Kathleen S Hruska; Wendy K Chung
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

8.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer.

Authors:  A C Antoniou; P P D Pharoah; P Smith; D F Easton
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

9.  BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?

Authors:  Bárbara Alemar; Cleandra Gregório; Josef Herzog; Camila Matzenbacher Bittar; Cristina Brinckmann Oliveira Netto; Osvaldo Artigalas; Ida Vanessa D Schwartz; Jordy Coffa; Suzi Alves Camey; Jeffrey Weitzel; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

Review 10.  Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.

Authors:  Maria Isabel Achatz; Maira Caleffi; Rodrigo Guindalini; Renato Moretti Marques; Angelica Nogueira-Rodrigues; Patricia Ashton-Prolla
Journal:  JCO Glob Oncol       Date:  2020-03
View more
  1 in total

1.  Clinical genomics testing: mainstreaming and globalising.

Authors:  Alisdair McNeill
Journal:  Eur J Hum Genet       Date:  2022-07       Impact factor: 5.351

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.